Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors:
Top Cited Papers
- 28 July 2015
- journal article
- guideline
- Published by Elsevier in Annals of Oncology
- Vol. 26 (suppl_5) , v31-v39
Abstract
Malignant pleural mesothelioma (MPM) is considered to be a relatively rare tumour. In Great Britain, the incidence in males is 3.4/100 000, in France it is 2.3/100 000 and in the Netherlands it is 3.2/100 000. In the last 10 years, the incidence of MPM has increased slightly, mainly due to the lag time of 30–50 years after exposure to asbestos and the banning of handling and importing this product in the late twentieth century. The World Health Organisation (WHO) estimates asbestos-related disease (ARD) accounts for 92 250 deaths per year globally [1]. Occupational exposure to asbestos accounts for more than 80% of the cases and makes MPM a preventable disease. Although the Western world is moving towards a levelling-off of ARD incidence, the continued use of asbestos in the developing world could lead to a global epidemic of MPM. Even though asbestos is banned in Europe, other developed countries have only controlled the import, but not abolished handling of asbestos products. Recently, a germline mutation in the BAP1 gene has been linked to predisposition in some cases of MPM [2]. Somatic mutations may also play a role in the development of MPM.Keywords
This publication has 55 references indexed in Scilit:
- Comparison of fibulin-3 and mesothelin as markers in malignant mesotheliomaThorax, 2014
- Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkersJournal of Clinical Pathology, 2013
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest GroupArchives of Pathology & Laboratory Medicine, 2013
- Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008Bulletin of the World Health Organization, 2011
- Germline BAP1 mutations predispose to malignant mesotheliomaNature Genetics, 2011
- Biomarkers for Malignant Pleural MesotheliomaMolecular Diagnosis & Therapy, 2008
- Non-invasive diagnosis of pleural malignancies: The role of tumour markersLung Cancer, 2007
- Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesotheliomaCancer, 2007
- Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reportsHistopathology, 2006
- Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trialThe Lancet, 2003